Popular peptide FAQ

Kisspeptin is notoriously unstable in plasma. Proteases degrade it within minutes unless samples are immediately stabilized with protease inhibitors (aprotinin 500 KIU/mL) and stored at −80°C. Collect blood into pre-chilled EDTA tubes containing protease inhibitor cocktail, centrifuge within 15 minutes, and snap-freeze plasma. Avoid freeze-thaw cycles. Aliquot samples before initial freezing. ELISA kits for kisspeptin have high cross-reactivity with degraded fragments, which inflates reported values. Use LC-MS/MS instead for accurate intact peptide quantification if precision is critical.

Continuous infusion or bolus dosing doesn't replicate physiological pulsatility. You need programmable micro-infusion pumps capable of delivering 50–100 ng kisspeptin-10 pulses every 60–90 minutes. Studies using pulsatile delivery (e.g., automated syringe pumps with timed intervals) show 3–5× greater LH secretion compared to continuous infusion at the same total dose. Alternatively, use optogenetic or chemogenetic activation of endogenous kisspeptin neurons (e.g., DREADD-expressing Kiss1-Cre mice) to achieve naturalistic pulse patterns without exogenous peptide administration.

Administer a single bolus of kisspeptin-10 (1 nmol/kg subcutaneously) and measure serum LH at 30, 60, and 120 minutes post-injection. If LH doesn't rise, the issue is downstream of the kisspeptin-GnRH axis. Either pituitary gonadotroph dysfunction or primary gonadal failure. A blunted response suggests that kisspeptin replacement won't solve the underlying pathology. Follow up with exogenous GnRH administration (100 mcg IV). If that triggers LH release, the defect is at the hypothalamic level and kisspeptin may still be therapeutic with dose optimization.

Pinealon reduces TNF-α and IL-1β secretion from activated microglia by 25–40% in vitro, making it suitable for traumatic brain injury, stroke, or neuroinflammation models. Pair it with mitochondrial support compounds when studying oxidative stress. The Energy Mitochondria Fatigue Bundle provides complementary modulators that address both inflammatory signaling and metabolic dysfunction in neurons under stress.

Pinealon is the compound class to prioritize. Its tripeptide structure allows passive diffusion through endothelial tight junctions plus active transport via amino acid carriers (EAATs), achieving brain tissue concentrations within 15–30 minutes of subcutaneous injection. Larger peptides like Cerebrolysin (10 kDa) cannot cross without IV administration, and intranasal peptides like Semax face unpredictable absorption variability. Pinealon eliminates those constraints entirely.

Use pinealon at 100–300 mcg/kg subcutaneously for protocols lasting 4–12 weeks. The tripeptide's mechanism. Direct DNA binding in promoter regions. Produces durable upregulation of neurotrophic factors that persists 2–4 weeks after the final dose. Unlike receptor agonists that require continuous presence to maintain effect, pinealon-induced BDNF and NGF expression remains elevated because the epigenetic changes it triggers are semi-permanent. Studies measuring synaptic protein levels four weeks post-treatment show retention of 60–70% of peak increases, compared to baseline.